

Ordered the Alzheimer's Risk Test yet?

Showcasing new test to predict risk of cognitive decline at New York symposium



The new IBX Alzheimer's Risk Test, powered by Cytox's *genoSCORE*[™] technology, will be showcased at the **Integrative Healthcare Symposium**, in New York from February 17-19. The test, for physician use only, can identify individuals most at risk of cognitive decline due to Alzheimer's disease, decades before any symptoms arise, and from just a simple saliva sample.

Delegates attending the conference should visit the Cytox booth to learn more about the product, and how it can support patient lifestyle changes to mitigate the risks of Alzheimer's, and delay the onset of disease.

For physicians in the US and Canada not attending the conference, you can still register for the product at: www.alzheimers-risk-test.com, or if you are interested in hearing more about the test or joining a webinar, please contact: alzheimers@vanguardpharma.com

Physicians in Europe can visit the European web portal at: www.genoscore-lab.com to register for the product, learn more about the test, or contact support@cytoxgroup.com to join a webinar.

Not at the New York meeting?

Please join us at future events:

Age Management Medicine Group
April 7-10, Miami, Florida

A4M Spring Congress
April 29-10, Hollywood, Florida

New research using *genoSCORE* published in JarLife

The Cytox team published new analysis of the ADNI data set, using its *genoSCORE*[™] Polygenic Risk Score test, in the Journal of Aging Research and Lifestyle (JarLife). Using the Preclinical Alzheimer Cognitive Composite (PACC) score profile, the research analysed nearly 600 individuals that were either APOE E3 homozygotes or APOE E3/E4 heterozygotes. The *genoSCORE*[™] test was able to predict those at greatest risk of cognitive decline over a 5 year period, regardless of APOE status. Of particular interest is its ability to identify APOE E3 homozygotes at risk of cognitive decline. This genotype accounts for approximately 60% of the general population and 35% of the AD population, but using existing methodologies would not be considered at higher genetic risk.

Growing public awareness of modifiable risk factors

A recent **Lancet paper** – estimating global dementia prevalence – has received broad media attention, including from the **BBC**. While the paper calls for more research and drug development in the field, it also highlights the importance of 12 modifiable risk factors – including hypertension, obesity, smoking, and physical inactivity – that, if managed correctly, could have a significant influence on disease progression and future prevalence. The *genoSCORE*[™] tests provide individuals with their genetic risk of Alzheimer's, empowering them to take action on the modifiable risks, potentially delaying the onset of symptoms, and slowing disease progression.